A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies

Anthony W. Tolcher, Joyce A. O'Shaughnessy, Raymond B. Weiss, Joanne Zujewski, Rick C. Myhand, Erasmus Schneider, Fran Hakim, Ronald Gress, Barry Goldspiel, Marianne H. Noone, Linda R. Brewster, Michelle R. Gossard, Kenneth H Cowan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Inhibitors of topoisomerase I and topoisomerase II have demonstrated synergy when administered sequentially in several tumor models while having a diminished antitumor effect when given concurrently. To explore the potential for clinical sequence-dependent synergy, we instituted a Phase I study of topotecan (a topoisomerase I inhibitor) followed by doxorubicin (a topoisomerase II inhibitor) in patients with advanced malignancies. Thirty- three patients with advanced malignancies or malignancies for whom no standard therapy exists were entered into the study. Topotecan was administered in escalating doses by 72-h continuous infusion on days 1, 2, and 3, followed by a bolus of doxorubicin given on day 5. To explore the hematological toxicity associated with this sequence, bone marrow aspirates were obtained both prior to the topotecan infusion and immediately prior to the doxorubicin in 10 patients to determine by fluorescence-activated cell sorting analysis whether CD34+ cell synchronization was occurring using this sequential schedule. Dose-limiting hematological toxicity occurred at the first dose-level in three of six patients. Therefore, we defined the maximum- tolerated dose (MTD) below our starting dose-level. Further dose-escalation and a new MTD were defined with the addition of granulocyte-colony stimulating factor (G-CSF). The MTD was, therefore, topotecan 0.35 mg/m2/day continuous i.v. infusion on days 1, 2, and 3, followed by doxorubicin 45 mg/m2 on day 5 without G-CSF, whereas the MTD with G-CSF was topotecan 0.75 mg/m2/day by 72-h continuous i.v. infusion, followed by doxorubicin 45 mg/m2 i.v. bolus on day 5. Ten patients with paired bone marrow aspirates obtained before topotecan and before doxorubicin administrations were available for evaluation. In 7 of 10 patients, there was an increase (16.6 ± 2.9% to 25.0 a: 3.5%; P < 0.02) in the proportion of CD34+ cells in S-phase 24 h after the topotecan infusion and prior to doxorubicin compared to the pretreatment values, whereas I patient had a decrease in the proportion of CD34+ cells in S phase and 2 patients had no change. Topotecan and doxorubicin with this sequence and schedule can be given safely; the dose- limiting toxicity is hematological toxicity. Alterations in the fraction of hematopoietic progenitor CD34+ cells in S-phase may account for the increased granulocytopenia and thrombocytopenia observed at relatively low dose levels of the combination with and without G-CSF.

Original languageEnglish (US)
Pages (from-to)755-760
Number of pages6
JournalClinical Cancer Research
Volume3
Issue number5
StatePublished - May 1 1997

Fingerprint

Topotecan
Doxorubicin
Maximum Tolerated Dose
Granulocyte Colony-Stimulating Factor
Neoplasms
S Phase
Topoisomerase I Inhibitors
Appointments and Schedules
Bone Marrow
Topoisomerase II Inhibitors
Type II DNA Topoisomerase
Agranulocytosis
Hematopoietic Stem Cells
Thrombocytopenia
Flow Cytometry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tolcher, A. W., O'Shaughnessy, J. A., Weiss, R. B., Zujewski, J., Myhand, R. C., Schneider, E., ... Cowan, K. H. (1997). A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clinical Cancer Research, 3(5), 755-760.

A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. / Tolcher, Anthony W.; O'Shaughnessy, Joyce A.; Weiss, Raymond B.; Zujewski, Joanne; Myhand, Rick C.; Schneider, Erasmus; Hakim, Fran; Gress, Ronald; Goldspiel, Barry; Noone, Marianne H.; Brewster, Linda R.; Gossard, Michelle R.; Cowan, Kenneth H.

In: Clinical Cancer Research, Vol. 3, No. 5, 01.05.1997, p. 755-760.

Research output: Contribution to journalArticle

Tolcher, AW, O'Shaughnessy, JA, Weiss, RB, Zujewski, J, Myhand, RC, Schneider, E, Hakim, F, Gress, R, Goldspiel, B, Noone, MH, Brewster, LR, Gossard, MR & Cowan, KH 1997, 'A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies', Clinical Cancer Research, vol. 3, no. 5, pp. 755-760.
Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E et al. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clinical Cancer Research. 1997 May 1;3(5):755-760.
Tolcher, Anthony W. ; O'Shaughnessy, Joyce A. ; Weiss, Raymond B. ; Zujewski, Joanne ; Myhand, Rick C. ; Schneider, Erasmus ; Hakim, Fran ; Gress, Ronald ; Goldspiel, Barry ; Noone, Marianne H. ; Brewster, Linda R. ; Gossard, Michelle R. ; Cowan, Kenneth H. / A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 5. pp. 755-760.
@article{1d54d64d991d45e7bd8d1ef6dfbf9906,
title = "A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies",
abstract = "Inhibitors of topoisomerase I and topoisomerase II have demonstrated synergy when administered sequentially in several tumor models while having a diminished antitumor effect when given concurrently. To explore the potential for clinical sequence-dependent synergy, we instituted a Phase I study of topotecan (a topoisomerase I inhibitor) followed by doxorubicin (a topoisomerase II inhibitor) in patients with advanced malignancies. Thirty- three patients with advanced malignancies or malignancies for whom no standard therapy exists were entered into the study. Topotecan was administered in escalating doses by 72-h continuous infusion on days 1, 2, and 3, followed by a bolus of doxorubicin given on day 5. To explore the hematological toxicity associated with this sequence, bone marrow aspirates were obtained both prior to the topotecan infusion and immediately prior to the doxorubicin in 10 patients to determine by fluorescence-activated cell sorting analysis whether CD34+ cell synchronization was occurring using this sequential schedule. Dose-limiting hematological toxicity occurred at the first dose-level in three of six patients. Therefore, we defined the maximum- tolerated dose (MTD) below our starting dose-level. Further dose-escalation and a new MTD were defined with the addition of granulocyte-colony stimulating factor (G-CSF). The MTD was, therefore, topotecan 0.35 mg/m2/day continuous i.v. infusion on days 1, 2, and 3, followed by doxorubicin 45 mg/m2 on day 5 without G-CSF, whereas the MTD with G-CSF was topotecan 0.75 mg/m2/day by 72-h continuous i.v. infusion, followed by doxorubicin 45 mg/m2 i.v. bolus on day 5. Ten patients with paired bone marrow aspirates obtained before topotecan and before doxorubicin administrations were available for evaluation. In 7 of 10 patients, there was an increase (16.6 ± 2.9{\%} to 25.0 a: 3.5{\%}; P < 0.02) in the proportion of CD34+ cells in S-phase 24 h after the topotecan infusion and prior to doxorubicin compared to the pretreatment values, whereas I patient had a decrease in the proportion of CD34+ cells in S phase and 2 patients had no change. Topotecan and doxorubicin with this sequence and schedule can be given safely; the dose- limiting toxicity is hematological toxicity. Alterations in the fraction of hematopoietic progenitor CD34+ cells in S-phase may account for the increased granulocytopenia and thrombocytopenia observed at relatively low dose levels of the combination with and without G-CSF.",
author = "Tolcher, {Anthony W.} and O'Shaughnessy, {Joyce A.} and Weiss, {Raymond B.} and Joanne Zujewski and Myhand, {Rick C.} and Erasmus Schneider and Fran Hakim and Ronald Gress and Barry Goldspiel and Noone, {Marianne H.} and Brewster, {Linda R.} and Gossard, {Michelle R.} and Cowan, {Kenneth H}",
year = "1997",
month = "5",
day = "1",
language = "English (US)",
volume = "3",
pages = "755--760",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies

AU - Tolcher, Anthony W.

AU - O'Shaughnessy, Joyce A.

AU - Weiss, Raymond B.

AU - Zujewski, Joanne

AU - Myhand, Rick C.

AU - Schneider, Erasmus

AU - Hakim, Fran

AU - Gress, Ronald

AU - Goldspiel, Barry

AU - Noone, Marianne H.

AU - Brewster, Linda R.

AU - Gossard, Michelle R.

AU - Cowan, Kenneth H

PY - 1997/5/1

Y1 - 1997/5/1

N2 - Inhibitors of topoisomerase I and topoisomerase II have demonstrated synergy when administered sequentially in several tumor models while having a diminished antitumor effect when given concurrently. To explore the potential for clinical sequence-dependent synergy, we instituted a Phase I study of topotecan (a topoisomerase I inhibitor) followed by doxorubicin (a topoisomerase II inhibitor) in patients with advanced malignancies. Thirty- three patients with advanced malignancies or malignancies for whom no standard therapy exists were entered into the study. Topotecan was administered in escalating doses by 72-h continuous infusion on days 1, 2, and 3, followed by a bolus of doxorubicin given on day 5. To explore the hematological toxicity associated with this sequence, bone marrow aspirates were obtained both prior to the topotecan infusion and immediately prior to the doxorubicin in 10 patients to determine by fluorescence-activated cell sorting analysis whether CD34+ cell synchronization was occurring using this sequential schedule. Dose-limiting hematological toxicity occurred at the first dose-level in three of six patients. Therefore, we defined the maximum- tolerated dose (MTD) below our starting dose-level. Further dose-escalation and a new MTD were defined with the addition of granulocyte-colony stimulating factor (G-CSF). The MTD was, therefore, topotecan 0.35 mg/m2/day continuous i.v. infusion on days 1, 2, and 3, followed by doxorubicin 45 mg/m2 on day 5 without G-CSF, whereas the MTD with G-CSF was topotecan 0.75 mg/m2/day by 72-h continuous i.v. infusion, followed by doxorubicin 45 mg/m2 i.v. bolus on day 5. Ten patients with paired bone marrow aspirates obtained before topotecan and before doxorubicin administrations were available for evaluation. In 7 of 10 patients, there was an increase (16.6 ± 2.9% to 25.0 a: 3.5%; P < 0.02) in the proportion of CD34+ cells in S-phase 24 h after the topotecan infusion and prior to doxorubicin compared to the pretreatment values, whereas I patient had a decrease in the proportion of CD34+ cells in S phase and 2 patients had no change. Topotecan and doxorubicin with this sequence and schedule can be given safely; the dose- limiting toxicity is hematological toxicity. Alterations in the fraction of hematopoietic progenitor CD34+ cells in S-phase may account for the increased granulocytopenia and thrombocytopenia observed at relatively low dose levels of the combination with and without G-CSF.

AB - Inhibitors of topoisomerase I and topoisomerase II have demonstrated synergy when administered sequentially in several tumor models while having a diminished antitumor effect when given concurrently. To explore the potential for clinical sequence-dependent synergy, we instituted a Phase I study of topotecan (a topoisomerase I inhibitor) followed by doxorubicin (a topoisomerase II inhibitor) in patients with advanced malignancies. Thirty- three patients with advanced malignancies or malignancies for whom no standard therapy exists were entered into the study. Topotecan was administered in escalating doses by 72-h continuous infusion on days 1, 2, and 3, followed by a bolus of doxorubicin given on day 5. To explore the hematological toxicity associated with this sequence, bone marrow aspirates were obtained both prior to the topotecan infusion and immediately prior to the doxorubicin in 10 patients to determine by fluorescence-activated cell sorting analysis whether CD34+ cell synchronization was occurring using this sequential schedule. Dose-limiting hematological toxicity occurred at the first dose-level in three of six patients. Therefore, we defined the maximum- tolerated dose (MTD) below our starting dose-level. Further dose-escalation and a new MTD were defined with the addition of granulocyte-colony stimulating factor (G-CSF). The MTD was, therefore, topotecan 0.35 mg/m2/day continuous i.v. infusion on days 1, 2, and 3, followed by doxorubicin 45 mg/m2 on day 5 without G-CSF, whereas the MTD with G-CSF was topotecan 0.75 mg/m2/day by 72-h continuous i.v. infusion, followed by doxorubicin 45 mg/m2 i.v. bolus on day 5. Ten patients with paired bone marrow aspirates obtained before topotecan and before doxorubicin administrations were available for evaluation. In 7 of 10 patients, there was an increase (16.6 ± 2.9% to 25.0 a: 3.5%; P < 0.02) in the proportion of CD34+ cells in S-phase 24 h after the topotecan infusion and prior to doxorubicin compared to the pretreatment values, whereas I patient had a decrease in the proportion of CD34+ cells in S phase and 2 patients had no change. Topotecan and doxorubicin with this sequence and schedule can be given safely; the dose- limiting toxicity is hematological toxicity. Alterations in the fraction of hematopoietic progenitor CD34+ cells in S-phase may account for the increased granulocytopenia and thrombocytopenia observed at relatively low dose levels of the combination with and without G-CSF.

UR - http://www.scopus.com/inward/record.url?scp=0030957029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030957029&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 755

EP - 760

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -